DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Germany
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
GXI logo

Gerresheimer AG Stock Price

XTRA:GXI Community·€1.0b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 34 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

GXI Share Price Performance

€29.16
-12.84 (-30.57%)
​
€25.26
Fair Value
€29.16
-12.84 (-30.57%)
15.4% overvalued intrinsic discount
€25.26
Fair Value
Price €29.16
AnalystConsensusTarget €25.26
AnalystHighTarget €44.18
AnalystLowTarget €20.00
Fri, 31 Jul 26
Fair Value€25.26
Share Pricen/a

GXI Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value €25.26 15.4% overvalued intrinsic discount

Ongoing Uncertainties And Downgrades Will Shape Efficiency Efforts Ahead

0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value €44.18 34.0% undervalued intrinsic discount

Secular Trends Will Drive Premium Drug Delivery Packaging Adoption

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value €20 45.8% overvalued intrinsic discount

Rising Production Costs And Regulatory Burdens Will Erode Margins

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
GXI logo
Gerresheimer
45.8% overvalued intrinsic discount

Rising Production Costs And Regulatory Burdens Will Erode Margins

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 3 Sep
Read Narrative
GXI logo
Gerresheimer
15.4% overvalued intrinsic discount

Ongoing Uncertainties And Downgrades Will Shape Efficiency Efforts Ahead

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 31 Jul
Read Narrative
GXI logo
Gerresheimer
34.0% undervalued intrinsic discount

Secular Trends Will Drive Premium Drug Delivery Packaging Adoption

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 19 Apr
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystLowTarget
GXI logo

GXI: Execution Risks Around Portfolio Disposals Will Pressure Shares Further

Fair Value: €20 45.8% overvalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
GXI logo

GXI: Reporting Delays And Accounting Concerns Will Restrain Confidence Despite China Expansion

Fair Value: €25.26 15.4% overvalued intrinsic discount
11 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
GXI logo

GXI: Reset After FY25 Warning Will Highlight Upside From Cautious FY26 Expectations

Fair Value: €44.18 34.0% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Undervalued with moderate growth potential.

1 Risk
3 Rewards
View Full Analysis

Gerresheimer AG Key Details

€2.3b

Revenue

€1.8b

Cost of Revenue

€548.3m

Gross Profit

€868.6m

Other Expenses

-€320.3m

Earnings

Last Reported Earnings
Nov 30, 2025
Next Reporting Earnings
Oct 15, 2026
-9.27
23.62%
-13.80%
198.6%
View Full Analysis

About GXI

Founded
1864
Employees
13528
CEO
Uwe Röehrhoff
WebsiteView website
www.gerresheimer.com

Gerresheimer AG, together with its subsidiaries, provides drug containment solutions in Germany and internationally. The company operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. It offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and containers, bottles, caps, closures, applicators, and accessories; development, industrialization, and contract manufacturing of drug delivery programs; project and quality management; and drug delivery devices, including inhalers, injection/auto injectors, and pen injectors. The company also provides diagnostic and medical devices comprising point-of-care tests, laboratory disposables, chemical and technical bottles, diagnostic and polymer vials, dropper bottles, PET bottles, and medical products comprising lancing devices, infusion sets, and disposable systems. In addition, it offers cosmetic packaging solutions, such as moulded glass flacons and jars; tubular glass ampoules, droppers, samplers and vials; and plastic packaging products, as well as pharmaceutical, laboratory, and regulatory affairs services. The company offers its products to pharmacy chains, supermarkets, and wholesalers. The company serves pharma, biotech, medical technology, diagnostics, cosmetics, glass containers, and food and beverage industries. Gerresheimer AG was founded in 1864 and is based in Düsseldorf, Germany.

Recent GXI News & Updates

User avatar
Narrative Update • Sep 03

GXI: Execution Risks Around Portfolio Disposals Will Pressure Shares Further

Gerresheimer’s updated analyst fair value target has moved from €12.50 to €20.00, with analysts pointing to higher price targets at several banks and a shift to more neutral ratings after recent portfolio disposals as key supports for this change. Analyst Commentary Recent research on Gerresheimer points to a more balanced view among analysts, with several moving to mid range ratings and setting price targets between €26.00 and €30.00.

Recent updates

No updates

Gerresheimer AG Competitors

1SXP logo

SCHOTT Pharma KGaA

Symbol: XTRA:1SXP
Market cap: €3.5b
DMP logo

Dermapharm Holding

Symbol: XTRA:DMP
Market cap: €1.9b
28L logo

PEPTONIC medical

Symbol: DB:28L
Market cap: €1.7b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide